| Predicate |
Object |
| contentType |
Journal Article|Research Support, Non-U.S. Gov't|Review |
| endingPage |
131 |
| issn |
0306-5251
1365-2125 |
| issueIdentifier |
2 |
| pageRange |
123-131 |
| publicationName |
British Journal of Clinical Pharmacology |
| startingPage |
123 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b8a819ceb0c7de73013ff46ed695481d |
| bibliographicCitation |
Duncan JS. The promise of new antiepileptic drugs. Brit J Clinical Pharma. 2002 Jan 18;53(2):123–31. doi: 10.1046/j.0306-5251.2001.01540.x. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4dbe2c372922f539d5babcbf651b79ed |
| date |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/PMC1874286
https://pubmed.ncbi.nlm.nih.gov/11851635
https://doi.org/10.1046/j.0306-5251.2001.01540.x |
| isPartOf |
https://portal.issn.org/resource/ISSN/1365-2125
https://portal.issn.org/resource/ISSN/0306-5251
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1743 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
The promise of new antiepileptic drugs |
| discusses |
http://id.nlm.nih.gov/mesh/M0001382 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D000927Q000494
http://id.nlm.nih.gov/mesh/D000927Q000627
http://id.nlm.nih.gov/mesh/D012640Q000188 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D000927Q000009
http://id.nlm.nih.gov/mesh/D013226Q000188
http://id.nlm.nih.gov/mesh/D006801 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9263
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID34312
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9191
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5665
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7617
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6522
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3878 |